C1

1. (Three times amended) A composition comprising (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, said composition further comprising less than 0.5% by weight (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one.

2. (Three times amended) The composition of claim 1, wherein the amount of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.25% or less by weight.

3. (Three times amended) The composition of claim 1, wherein the amount of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.1% or less by weight.

4. (Three times amended) An improvement in a process for preparing (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, the improvement comprising aging crystals of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in the presence of water for a period of time of at least 24 hours.

5. (Amended) The improvement of claim 4 wherein the period of time lasts 3-6 days.

6. (Amended) The improvement of claim 4, wherein the crystals are formed in the last step of a synthesis comprising the steps of:

a. reacting (7α, 17α) -3, 3-dimethoxy-17-hydroxy-7- methyl-19-norpregn-5 (10) -en-20-yn-3-one in an organic solvent with a weak acidic aqueous solution,

b. pouring out the solution in water which is slightly alkaline, and

c. washing the crystals with water which is slightly alkaline.

C2

9. (Three times amended) A dosage unit of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, said dosage unit having less than 5% by weight of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one over a time period, said dosage unit comprising:

a pharmaceutically suitable solid carrier,

said (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in an amount of less than 2.50 mg per dosage unit, and

less than 5% by weight of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one.

C2 Cont'd

10. (Amended) The dosage unit of claim 9, wherein the (7α, 17α) -17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one is present in an amount of 1.25 mg or less.

11. (Amended) The dosage unit of claim 9, wherein the (7α, 17α) -17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one is present in an amount of 0.625 mg or less.

C3

13. (Amended) The dosage unit of claim 9, wherein at a time period of 6 months the amount of (7α, 17α) -17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 3% or less by weight of the amount of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one.

14. (Amended) The dosage unit of claim 9, wherein the time period is at least 1 year.

15. (Amended) The dosage unit according to claim 9, wherein the time period is at least 2 years.

16. (Amended) The dosage unit of claim 13, wherein the amount of (7α, 17α) -17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 2% or less by weight of the amount of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10) -en-20-yn-3-one.

17. (Amended) The dosage unit of claim 14, wherein the time period is at least 1½ years.

C4

19. (New) A granulate comprising (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, wherein the granulate comprises (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one in an amount less than 0.5% and the amount of water incorporated in the granulate ranges from 5.5-7%.

20. (New) The granulate of claim 19, wherein the amount of water incorporated in the granulate is at least 6%.